17 August 2021
: Case report 
Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction, Rare disease, Clinical situation which can not be reproduced for ethical reasons
Sri Harsha Boppana1A*, Nageswara Rao Dulla2EF, Bryce D. Beutler3EF, Nageshwara Gullapalli1ADEFG, Ratinder Kaur14DEDOI: 10.12659/AJCR.932888
Am J Case Rep 2021; 22:e932888
Table 1. Characteristics of patients with checkpoint inhibitor-induced eosinophilic fasciitis.
| Sex/age* | Type of malignancy | Type of CPI | Months until the onset of symptoms | Increased eosinophil counts | CPK elevation | Indicative biopsy | CPI discontinuation | Specific treatment | Malignancy outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| F/43 | Melanoma | Nivolumab | 14 | No | No | Yes | Not reported | GCs, IVIg | CR | Parker []20 |
| M/48 | Lung adeno- carcinoma | Atezolizumab | 6 | Yes | Yes | Yes | Yes | GCs, MTX | DP | Chan []21 |
| F/48 | Triple-negative breast cancer (TNBC) | Atezolizumab | 7.5 | Yes | No | Yes | Yes | No | PR | Wissam []22 |
| F/51 | Melanoma | Pembrolizumab | 18 | Yes | No | Yes | Discontinued 1 month before the onset of symptoms | GCs | CR | Khoja []23 |
| F/53 | Melanoma | Pembrolizumab | 8 | Not reported | Not reported | Yes | Yes | GCs, MTX | CR | Lidar []24 |
| M/55 | Melanoma | Nivolumab | 24 | Yes | No | Yes | Yes | GCs, MTX | CR | Rischin []25 |
| F/56 | Lung adeno- carcinoma | Nivolumab | 9 | Yes | No | Yes | Yes | GCs, MTX | SD | Le Tallec []26 |
| M/64 | Melanoma | Nivolumab | 11 | Yes | No | Yes | Yes | GCs, MTX, IVIg | Response | Ollier []27 |
| M/65 | Bladder cancer | Ipilimumab plus nivolumab initially, followed by nivolumab monotherapy | 16 | Yes | Not reported | Yes | Yes | GCs, MTX | DP | Lencina []28 |
| M/70 | Melanoma | Pembrolizumab | 8 | Yes | Not reported | No | Yes | GCs, MTX | PR | Chan []21 |
| F/71 | Melanoma | Nivolumab | 3 | Yes | No | Yes | Yes | GCs, MTX | CR | Chan []21 |
| F/77 | Melanoma | IPILIMUMAB (early withdrawal due to colitis), followed by pembrolizumab monotherapy | 22 | Yes | Yes | No | Yes | GCs, MTX | CR | Toussaint []29 |
| F/72 | Squamous cell carcinoma | Cemiplimab | 12 | No | Not reported | Yes | Yes | GCs, sulfasala-zine, hydroxychlo-roquine | CR | Current report |
| * Age is that at the time of CPI initiation. CPI – checkpoint inhibitor; CR – complete response; PR– partial response; DP – disease progression; SD – stable disease; GCs – glycocorticosteroids; MTX – methotrexate; IVIg – intravenous immunoglobulin. | ||||||||||